Denosumab injection
Products billed under this code include Prolia, Xgeva.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Prolia, Xgeva.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Prolia | Amgen Inc | 55513-0710-01 | 60 | $1,791.36 |
| Prolia | Amgen Inc | 55513-0710-21 | 60 | $1,791.36 |
| Xgeva | Amgen Inc | 55513-0730-01 | 120 | $3,582.72 |
| Xgeva | Amgen Inc | 55513-0730-21 | 120 | $3,582.72 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $29.856 | −$0.245 | 1 MG | Denosumab injection | v1, posted September 17, 2026 |
| 3Q26 | $30.101 | +$0.594 | 1 MG | Denosumab injection | v1, posted September 15, 2026 |
| 2Q26 | $29.507 | +$0.05 | 1 MG | Denosumab injection | v1, posted September 15, 2026 |
| 1Q26 | $29.457 | +$0.077 | 1 MG | Denosumab injection | v1, posted September 15, 2026 |
| 4Q25 | $29.38 | +$0.143 | 1 MG | Denosumab injection | v1, posted September 8, 2026 |
| 3Q25 | $29.237 | +$1.428 | 1 MG | Denosumab injection | v1, posted March 10, 2026 |
| 2Q25 | $27.809 | +$0.153 | 1 MG | Denosumab injection | v1, posted March 10, 2026 |
| 1Q25 | $27.656 | +$0.696 | 1 MG | Denosumab injection | v1, posted December 19, 2025 |
| 4Q24 | $26.96 | +$0.211 | 1 MG | Denosumab injection | v1, posted June 11, 2025 |
| 3Q24 | $26.749 | +$1.56 | 1 MG | Denosumab injection | v1, posted June 11, 2025 |
| 2Q24 | $25.189 | −$0.009 | 1 MG | Denosumab injection | v1, posted March 11, 2025 |
| 1Q24 | $25.198 | +$0.981 | 1 MG | Denosumab injection | v1, posted December 19, 2024 |
| 4Q23 | $24.217 | +$0.025 | 1 MG | Denosumab injection | v1, posted October 10, 2024 |
| 3Q23 | $24.192 | +$1.174 | 1 MG | Denosumab injection | v1, posted June 5, 2024 |
| 2Q23 | $23.018 | −$0.049 | 1 MG | Denosumab injection | v1, posted February 23, 2024 |
| 1Q23 | $23.067 | +$0.557 | 1 MG | Denosumab injection | v1, posted December 6, 2023 |
| 4Q22 | $22.51 | +$0.255 | 1 MG | Denosumab injection | v1, posted June 22, 2023 |
| 3Q22 | $22.255 | +$0.995 | 1 MG | Denosumab injection | v1, posted June 9, 2023 |
| 2Q22 | $21.26 | +$0.055 | 1 MG | Denosumab injection | v1, posted December 14, 2022 |
| 1Q22 | $21.205 | +$0.016 | 1 MG | Denosumab injection | v1, posted June 8, 2022 |
| 4Q21 | $21.189 | +$0.217 | 1 MG | Denosumab injection | v1, posted June 2, 2022 |
| 3Q21 | $20.972 | +$0.878 | 1 MG | Denosumab injection | v1, posted June 2, 2022 |
| 2Q21 | $20.094 | −$0.013 | 1 MG | Denosumab injection | v1, posted March 1, 2022 |
| 1Q21 | $20.107 | – | 1 MG | Denosumab injection | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.